C3.AI, INC. (AI): what the price requires

At today's price, C3.AI, INC. (AI) is priced for +20.7% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-13 · Source: https://boothcheck.com/report/AI

Headline

FieldValue
TickerAI
CompanyC3.AI, INC.
Current price$9.10/sh
CompositionSubscription 84% / Professional services 16%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid2.4x
Steady-state operating margin assumed24.2%
Implied growth20.7%

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 14.3% cost of capital with 4% terminal growth over a 5-year stage, holding a 24.2% terminal operating margin (60.6% gross margin x the 40% mature-conversion prior); each 1pp of cost of capital moves the implied revenue growth ~6.5pp.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.42σ
sustained it ~5 years at this level42%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple; asset-based land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.90x2expensive
Earnings—0—
Relative0.53x1justifies
Growth—0—

Families that justify the price: Relative Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=3)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$17.320.53xyesP/S fallback (negative EPS): Sector P/S 8.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$5.071.79xyesReference only (book value floor): BV/sh $5.07, ROE negative
Two-Stage Excess ReturnAsset$4.562.00xyesReference only (book value with convergence): BV/sh $5.07, ROE converges to ke
Discounted Future Market CapGrowth$3.632.51xnoRev $0.3B, growth -15% (input: historical growth; tapered), Terminal P/S: 3.6x / 4.2x / 4.8x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$17.320.53xnoRevenue $0.31B × sector P/S 8.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$621.9m
Share count CAGR (dilution)7.8%
Burning cashyes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

The company is not earning a profit, so the price is set against sales. At about 2.9 times revenue, the market is paying for the business to eventually reach a roughly 24 percent operating margin and grow at its self-funding ceiling for about seven years.

Fiscal 2026 revenue was $250.3 million, within guidance, but the GAAP operating loss was $498.5 million. The non-GAAP operating loss of $217.8 million strips out stock compensation and restructuring, and the gap between the two is the dilution shareholders absorb.

Founder Tom Siebel resumed the CEO role in May 2026, and a restructuring plan targets about $135 million in annualized cost and cash-burn savings. The company holds roughly $575 million of cash and no debt, which funds the turnaround attempt the price is underwriting.

Bull Case

Start with what the market is paying for, because the price is more interpretable than the headline loss. C3.ai earns no operating profit, so the valuation is set against sales rather than earnings, and at roughly 2.9 times revenue the price embeds a specific future: an eventual operating margin near 24 percent and revenue growth held at the self-funding ceiling for about seven years. That is a bet on a software model that has not yet proven its economics, but it is also a relatively contained one. The static asset method reads the stock as expensive, while the peer-multiple frame, comparing C3.ai to other enterprise-software names that trade on revenue, supports something close to the current price. The market is not pricing a fantasy; it is pricing a high-margin software outcome that the company has yet to deliver.

The business has the pieces that could make that outcome real. Subscription revenue is about 84 percent of the mix, which is the recurring, scalable part investors want, and fiscal 2026 revenue of $250.3 million landed within the guided range, so management is at least forecasting its own near-term results accurately. The product is enterprise AI application software, a category with genuine corporate demand, and the company has marquee references and a long-standing alliance through Baker Hughes that has historically been a meaningful revenue source. If C3.ai can convert pilot deployments into broad enterprise rollouts as corporate AI budgets expand, the subscription base compounds against a largely fixed cost structure.

The balance sheet buys the time the turnaround needs. The company holds roughly $575 million in cash, cash equivalents and investments with no debt, so it can fund continued losses while it restructures. Management's plan targets about $135 million in annualized non-GAAP cost and cash-burn savings, with most of the non-employee savings landing in the back half of fiscal 2027, and the non-GAAP operating loss of $217.8 million already came in better than guidance. A cash-rich, debt-free company narrowing its losses while founder Tom Siebel retakes the helm is the kind of situation where, if execution improves, the gap between a revenue-multiple price and the asset floor closes upward rather than downward.

Bear Case

The governance and capital-allocation record is where the skepticism starts, because it is what the loss numbers expose. Fiscal 2026 produced a GAAP operating loss of $498.5 million against just $250.3 million of revenue, and the company's own filing concedes it has incurred "losses and accumulated deficit" reflecting the "substantial investments we made to acquire new customers" and warns that if it "is unable to achieve and sustain profitability, the val" of the stock could decline (FY2025 10-K, accession 0001628280-25-032604). The chasm between the GAAP loss and the $217.8 million non-GAAP loss is mostly stock-based compensation, which is a real transfer of ownership away from existing holders. A business that loses roughly two dollars on the income statement for every dollar of revenue, and pays its people heavily in shares, is diluting the very investors the revenue-multiple is supposed to reward.

The leadership setup adds to the uncertainty rather than resolving it. Founder Tom Siebel resumed the CEO role in May 2026 after stepping back, with the prior leader continuing as president beneath him. Founder returns can steady a company, but the need for one signals an unsettled strategy, and the turnaround plan, a restructuring expected to save about $135 million annually with most benefits only in the back half of fiscal 2027, is a promise rather than a result. The price already credits the eventual 24 percent margin; the company is still cutting costs to stop the bleeding.

The revenue base carries concentration risk on top of the profitability problem. C3.ai has leaned on a small number of large relationships, and the filing details the Baker Hughes arrangement, including subscription revenue from Baker Hughes that the company recognized at meaningfully different levels across years (FY2025 10-K, accession 0001628280-25-032604). When a single partner can swing reported revenue, the durable-growth assumption embedded in the price becomes fragile. Inverting the current price shows the market expecting growth at the self-funding ceiling sustained for nearly seven years, a pace only about a quarter of comparable fast-growers held. A loss-making, founder-dependent, concentration-exposed software company priced at the elevated end of what fundamentals support has many ways to disappoint and a thin margin for any of them.

Valuation

C3.ai earns no normal operating profit, so the price is set against its sales rather than its earnings. On that basis the price is justified only by the relative-multiple frame; the asset-based method reads the stock as expensive, and the blended central value across the applicable methods sits near $5 against the $10.32 (as of June 27, 2026) price. The current operating margin is deeply negative, so there is no earnings power to anchor on, and the valuation rests entirely on what the revenue base is assumed to become.

Inverting the current price makes the bet explicit. At about 2.9 times revenue, the price implies the business eventually earns an operating margin near 24 percent and grows revenue at its self-funding ceiling for roughly seven years. The near-term growth rate is within what the company has recently shown, so the stretch is in the duration and in the assumed swing from a deep loss to a healthy software margin. Historically only about a quarter of comparable fast-growers sustained that pace over a window this long. The balance sheet, with roughly $575 million of cash and no debt, gives the company the runway to attempt it, and the restructuring targeting about $135 million in annualized savings is the mechanism meant to bend the loss curve. But the investment case is not about the multiple being cheap or dear today; it is about whether a company that lost $498.5 million on a GAAP basis against $250.3 million of revenue can credibly become a 24 percent-margin business before the cash and patience run out. The reward exists if the turnaround works; the price gives little protection if it does not.

Catalysts

The restructuring and the loss curve are the central catalysts. Management's plan targets about $135 million in annualized non-GAAP cost and cash-burn savings, with most non-employee savings expected in the back half of fiscal 2027. The fiscal 2026 non-GAAP operating loss of $217.8 million already beat guidance, so the proof points to watch are whether the burn keeps narrowing and whether the savings arrive on the promised schedule. Each quarterly print is a check on cash runway against the roughly $575 million on hand.

The leadership transition is the near-term event. Founder Tom Siebel resumed the CEO role in May 2026, with Stephen Ehikian continuing as president. How Siebel resets strategy, pricing, and the go-to-market approach will shape whether revenue reaccelerates, and any change to guidance under the new structure is a direct catalyst. Watch the first full results reported under his renewed leadership.

Revenue trajectory and large-customer activity are the swing factors. Fiscal 2026 revenue of $250.3 million landed within guidance, but the durable-growth assumption in the price depends on broadening the customer base beyond a few large relationships. New enterprise wins, renewals or expansions, and the status of the long-standing Baker Hughes alliance are the items to track, since concentration in a single partner can move reported revenue in either direction. Quarterly results remain the main proof point on whether growth and margin are bending toward what the price assumes.

Peer Cohorts (Per Segment, With Filing Citations)

C3.ai (consolidated) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive AI report on boothcheck